The Zacks analyst believes that in 2020, Lilly’s revenue growth is likely to be driven by higher demand for newer drugs like Trulicity, Jardiance, Taltz, Verzenio, Basaglar, Emgality as well as newly launched Baqsimi and Reyvow.(You can read the full research report on Eli Lilly here >>>) Shares of Charter Communications have gained +22% over the past year against the Zacks Cable TV industry’s fall of -11.1%.